CN113750032A - Oral abiraterone medicinal composition and preparation method and application thereof - Google Patents

Oral abiraterone medicinal composition and preparation method and application thereof Download PDF

Info

Publication number
CN113750032A
CN113750032A CN202011642502.6A CN202011642502A CN113750032A CN 113750032 A CN113750032 A CN 113750032A CN 202011642502 A CN202011642502 A CN 202011642502A CN 113750032 A CN113750032 A CN 113750032A
Authority
CN
China
Prior art keywords
abiraterone
surfactant
acid
active ingredient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011642502.6A
Other languages
Chinese (zh)
Other versions
CN113750032B (en
Inventor
唐珊
黄依娟
石凯荣
张丽月
赵小芳
陈礼莉
李英富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Haibowei Pharmaceutical Co ltd
Original Assignee
Chengdu Haibowei Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Haibowei Pharmaceutical Co ltd filed Critical Chengdu Haibowei Pharmaceutical Co ltd
Publication of CN113750032A publication Critical patent/CN113750032A/en
Application granted granted Critical
Publication of CN113750032B publication Critical patent/CN113750032B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses an oral abiraterone medicinal composition and a preparation method and application thereof. The preparation of the invention increases the drug-loading rate of the abiraterone acetate, improves the bioavailability of the abiraterone acetate medicinal preparation, can reduce the difference of blood concentration before meal and after meal and is convenient to take by compounding the abiraterone acetate with the fatty acid. Meanwhile, the abiraterone medicinal preparation disclosed by the invention is few in components, good in stability, simple in preparation process, capable of realizing large-scale industrial production and convenient to produce and transport.

Description

Oral abiraterone medicinal composition and preparation method and application thereof
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral abiraterone pharmaceutical composition and a preparation method and application thereof.
Background
Abiraterone acetate is a derivative of steroid progesterone developed by Johnson corporation, is a prodrug of Abiraterone, and can be rapidly hydrolyzed and deacetylated to Abiraterone in vivo. Abiraterone inhibits 17 α -hydroxylase/C17, 20-lyase (CYP17), which is expressed in testicular, adrenal and prostate tumor tissues and is essential for androgen biosynthesis. The drug molecule has been approved in many countries for metastatic Castration Resistant Prostate Cancer (CRPC), and abiraterone acetate has also been incorporated into the world health organization "basic drug list".
The chemical name of the abiraterone acetate is (3 beta) -17- (3-pyridyl) androstane-5, 16-diene-3-yl acetate, and the molecular formula is C26H33NO2And has a molecular weight of 391.55 and the formula:
Figure BDA0002880929890000011
it is a white to off-white, non-hygroscopic crystalline powder, a lipophilic compound having an octanol-water partition coefficient (logP) of 5.12 and an aromatic nitrogen pKa of 5.19, and being hardly soluble in water. BCS is classified as a class IV compound, hypo-lytic and hypotonic.
Zytiga is a primary drug of abiraterone acetate, which is a tablet, with the specification of 250mg, the daily dose of 1000mg, four tablets per day, wherein the inactive ingredients are lactose monohydrate, croscarmellose sodium, microcrystalline cellulose, povidone, colloidal silicon dioxide, magnesium stearate and sodium lauryl sulfate.
According to the information disclosed by Zytiga original medicine, the medicine is orally taken in a human body mass balance research14After C-abiraterone acetate, about 88% of the radioactive dose was found in feces (55% of abiraterone acetate, 22% of abiraterone, and about 5% in urine. Thus, Zytiga has very low bioavailability, and a single administration of 1000mg results in only less than 10% of the drug being absorbed. The extremely low bioavailability results in waste of the raw material drug and increased cost of administration for patients.
Furthermore, according to the original prescription information, Zytiga must be taken on an empty stomach and food should not be consumed at least two hours before and one hour after the administration. This is because the original study discloses the C of mCRPC patients at a dose of 1000mg per daymaxThe steady state mean was 226 + -178 ng/mL, the AUC steady state mean was 1173 + -690 ng.hr/mL, and the Zytiga protocol emphasizes that systemic exposure to abiraterone acetate increased when given with food. Specifically, there was an approximately 7-fold and 5-fold increase in abiraterone Cmax and AUC 0- ∞ respectively when abiraterone acetate was administered with a low fat diet (7% fat, 300 calories); abiraterone Cmax and AUC 0- ∞ increase about 17-fold and 10-fold, respectively, when given with a high fat diet (57% fat, 825 calories). The medicine taking mode caused by the pharmacokinetic characteristics of Zytiga brings great inconvenience to the life of a patient, and meanwhile, certain safety risk is brought due to higher exposure after the high-fat food is taken by mistake.
In addition, Zytiga, a size of 250mg, has low bioavailability, requires a daily dose of up to 1000mg, is taken four times a day, and has a tablet weight of up to 736mg, which causes difficulty in oral administration for patients. Particularly, the main disease population of the prostate cancer is old men, and the old population is often characterized by dysphagia, so that Zytiga also has the clinical problem of poor oral compliance.
In 2018, in order to solve the above problems of Zytiga in the original research, Sun Pharmaceutical company in India developed and marketed an improved preparation YONZA of Abiraterone acetate. YONZA adopts micronization technology, improves the dissolution rate of the medicine, doubles the bioavailability of the original preparation Zytiga, takes 500mg orally, which is equivalent to 1000mg in the original preparation, and has low bioavailability according to the bioavailability of the original preparation. Although the difference in absorption by the food is reduced, there is still a large deviation. Meanwhile, the specification is 125mg, 4 tablets are taken once a day, and the problem of certain oral compliance still exists for patients with dysphagia. Thus, the advent of YONZA did not reliably solve the problems of Zytiga in the prior art.
Patent document CN107278152A adopts polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and sodium deoxycholate to form a compound by a microfluid flow meter, and then spray drying or freeze drying is performed to form a solid. The complex can reduce food effect and give up on an empty stomach for taking medicine. In vivo experiments, bioavailability was increased 11-fold in beagle dogs and 4-fold in adult men compared to the original study. However, the technology has the problems of complex preparation process and high energy consumption, and a large amount of organic solvent tetrahydrofuran is used in the technology, so that the problems of environmental protection and production safety exist.
Patent document CN110538150A relates to a pharmaceutical composition containing abiraterone acetate, and a preparation method and application thereof, wherein the auxiliary materials comprise: at least one oil phase, at least one emulsifier and at least one co-emulsifier. In vivo testing in beagle dogs, example 1 showed a 10-fold increase in bioavailability over the original study, while overcoming the food effect. However, this technique also has two problems: (1) the formula of the patent contains ethanol, and the ethanol plays an important role in increasing the solubility of API and reducing the particle size of milk particles in the formula, is very easy to volatilize, and can bring influence on the stability and curative effect of the product. (2) The drug loading in the technology is still limited, the drug loading is 20-100mg/mL, if the drug is improved by 11 times in CN10728152A beagle dogs and 4 times in human bodies, the bioavailability of the drug in human bodies is improved by 3.5 times, the drug dosage per time is 286mg, the oil content in soft capsules per time is 14.3-2.86 mL according to the drug loading calculation, and 0# capsule can only fill 0.5mL per capsule, which means that 25-6 large-size capsules need to be taken orally by patients each time, and the practical application in clinic is poor.
Patent document CN111012745A discloses an abiraterone oral emulsion and a preparation method thereof. In vivo tests show that in beagle dogs, the bioavailability of one embodiment is improved by 3.4 times, the technology does not remarkably improve the bioavailability, and the emulsion form is not easy to store and transport and has poor oral feeling of patients.
Patent document PCT/EP2016/056689 discloses a lipid composition comprising abiraterone acetate. The technique eliminates the food effect and in the beagle in vivo test, the bioavailability is improved by 5 times compared with the original research. However, the drug loading of the technology is low, wherein the drug loading of the embodiment with the highest bioavailability is 6%, and the patient needs to take 9 capsules with large size orally each time according to the conversion of the bioavailability of beagle dogs in human and the calculation of the drug loading.
Therefore, the existing abiraterone preparation has the problems of low bioavailability, low drug loading, inconvenient administration, poor stability, inconvenient transportation, complex production process, large environmental pollution and the like, and greatly influences the commercial development of the existing abiraterone preparation, so that the development of the abiraterone preparation which can improve the bioavailability and the drug loading, reduce the difference of blood concentration before meals, has simple and stable prescription process and convenient transportation has important significance for the clinical application of abiraterone or abiraterone acetate is realized.
Disclosure of Invention
The invention mainly solves the technical problem of providing the abiraterone medicinal composition which is added with fatty acid as an oil solvent and has high bioavailability and high drug loading.
Many studies have been made to improve the bioavailability of abiraterone-related drugs and the drug-taking experience of patients, but the improvement effect of oral preparations is still not ideal.
Some researchers consider adjusting the type of preparation, and prepare the medicine into properties such as inhalant or oral spray, etc., so as to change the absorption mode of the medicine and improve the bioavailability of the medicine, but the inhalant or oral spray is generally used for local administration, such as treatment of halitosis, sore throat, respiratory diseases, etc.
Although theoretically, inhalants or oral sprays can also enter the body through abundant capillaries of mucous membranes, the inhalants often cause burden to the lungs, and if not necessary for pulmonary administration, long-term use of the inhalants can cause influence on the health of the lungs; the secretion and swallowing of saliva in the oral cavity can easily cause that the medicine is not absorbed in time and is carried into the stomach by the saliva; therefore, the two preparations are difficult to be absorbed by the whole body, the individual difference is very large in practical application and administration, the pressure of a patient on the atomizer, the batch number of the atomizer (which can influence the size and the scattering position of fog drops), the salivary secretion speed of the patient and the swallowing frequency can be influenced, the bioavailability of the medicine is greatly influenced, uncertain factors are many, and the safety risk is high. In addition, the cost of an inhalant or oral spray is often many times higher than that of an oral drug, which imposes an economic burden on the patient.
Therefore, the abiraterone capable of being orally taken and acting on the whole body is improved as much as possible, the universality and the safety are higher, and the drug-loading rate and the bioavailability of the abiraterone oral preparation can be obviously improved by adopting a new oil solvent.
In the present invention, the "oral preparation" refers to a preparation absorbed through the gastrointestinal tract after administration, and does not include a mouth spray absorbed in a sublingual manner.
In order to solve the problems, the invention provides an abiraterone medicinal composition which comprises an active ingredient and an oil solvent, wherein the active ingredient is abiraterone acetate and/or abiraterone, and the oil solvent is fatty acid.
Further, the composition comprises the following components in parts by weight: 1-80% of active ingredients and the balance of fatty acid; further, the active ingredient content is 1% to 50%, preferably 5% to 40%, more preferably 10% to 30%.
In some embodiments of the present invention, the mass fraction of the active ingredient is 4% to 20%, preferably 4 to 15.5%.
In the invention, the fatty acid is selected from one or more of linolenic acid, oleic acid, linoleic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, eicosapentaenoic acid, docosahexaenoic acid and acetic acid, preferably linolenic acid and/or oleic acid, and more preferably oleic acid.
The invention also provides an abiraterone medicinal composition which comprises an active ingredient and a surfactant, wherein the active ingredient is abiraterone acetate and/or abiraterone.
Further, the surfactant content is 0% to 70% (not 0%), preferably 10% to 55%, more preferably 20% to 30%.
In some embodiments of the present invention, the surfactant is 20 to 50% by mass.
In the invention, the surfactant is selected from nonionic surfactants with HLB value more than 8, and is further selected from one or more of polysorbate surfactants (such as Tween 20, Tween 40, Tween 60, Tween 80, Tween 85 and the like), polyoxyethylene fatty acid ester surfactants (such as Myrij-45, Myrij-49, Myrij-51, Myrij-52, Myrij-53 and the like), polyoxyethylene fatty alcohol ether surfactants (such as Brij-30, Brij-35 and the like), polyoxyethylene-polyoxypropylene copolymer surfactants (such as poloxamer 188 and the like) and soluplus.
Further, the surfactant is selected from one or more of caprylic/capric acid polydiethylene glycol glyceride, tween 80, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene 35 castor oil and polyethylene glycol 15 hydroxystearate, preferably one or more of tween 80, polyoxyethylene 40 hydrogenated castor oil and polyoxyethylene 35 castor oil, and more preferably polyoxyethylene 40 hydrogenated castor oil and/or polyoxyethylene 35 castor oil.
The invention also provides an abiraterone medicinal composition which comprises an active ingredient and a cosurfactant, wherein the active ingredient is abiraterone acetate and/or abiraterone;
further, the co-surfactant content is from 0% to 70% (other than 0%), preferably from 10% to 55%, more preferably from 20% to 30%.
In some embodiments of the invention, the co-surfactant is present in an amount of 0% to 50%, preferably 5% to 40% by weight.
In the invention, the cosurfactant is selected from one or more of propylene glycol, ethanol, PEG400, glycerol, diethylene glycol monoethyl ether, caprylic capric acid polyethylene glycol glyceride, polyglycerol oleate, propylene glycol monocaprylate and oleic acid polyethylene glycol glyceride, is further selected from one or more of propylene glycol, ethanol, PEG400, glycerol and diethylene glycol monoethyl ether, is preferably propylene glycol and/or diethylene glycol monoethyl ether, and is more preferably propylene glycol.
The invention also provides an abiraterone medicinal composition which comprises the following components in parts by weight: 5 to 40 percent of abiraterone acetate, 10 to 75 percent of oleic acid, 10 to 55 percent of surfactant and 10 to 40 percent of cosurfactant.
Further, the abiraterone pharmaceutical composition comprises the following components in parts by weight: 10 to 30 percent of abiraterone acetate, 30 to 50 percent of oleic acid, 20 to 40 percent of surfactant and 15 to 30 percent of cosurfactant.
Furthermore, the abiraterone pharmaceutical composition can be a prescription comprising the following components in parts by weight: 15.2% abiraterone acetate, 38.2% oleic acid, 23.3% polyoxyethylene 35 castor oil and 23.3% propylene glycol, or 12.3% abiraterone acetate, 30.7% oleic acid, 28.5% polyoxyethylene 35 castor oil and 28.5% propylene glycol, or 10.3% abiraterone acetate, 22.5% oleic acid, 33.6% polyoxyethylene 35 castor oil and 33.6% propylene glycol, or 7.4% abiraterone acetate, 18.5% oleic acid, 37.3% polyoxyethylene 35 castor oil and 36.8% propylene glycol, or 4.0% abiraterone acetate, 10.1% oleic acid, 47.5% polyoxyethylene 35 castor oil and 38.4% propylene glycol.
The invention also provides an abiraterone pharmaceutical composition, which comprises an active ingredient and an antioxidant; further, the content of the antioxidant is 0.005-0.5%, preferably 0.01-0.2%.
Further, the antioxidant is selected from tert-butyl p-hydroxyanisole and/or dibutyl hydroxy toluene.
The invention also provides an abiraterone medicinal composition which comprises an active ingredient and cholate; furthermore, the content of the cholate is 20-70%.
In the invention, the cholate is sodium glycocholate and/or sodium taurocholate.
The abiraterone pharmaceutical composition comprises an active ingredient and auxiliary materials, wherein the auxiliary materials can comprise any commonly used auxiliary materials in the field, such as one or more of the fatty acid, the surfactant, the cosurfactant, the antioxidant, the cholate and the like, and can also comprise a preservative, a metal ion chelating agent and the like, and for example, the abiraterone pharmaceutical composition can be in a combination form as follows:
two components: "active ingredient" + "any of fatty acids, surfactants, co-surfactants, antioxidants, cholates, preservatives, metal ion chelators", for example:
active ingredient + fatty acid; active ingredient + surfactant; active ingredient + co-surfactant; active ingredient + antioxidant; active ingredient + cholate; active ingredient + preservative; active ingredient + metal ion chelating agent;
② three components: "active ingredient" + "any two of fatty acids, surfactants, co-surfactants, antioxidants, cholates, preservatives, metal ion chelators", for example:
active ingredient + fatty acid + surfactant; active ingredient + fatty acid + co-surfactant; active ingredient + fatty acid + antioxidant; active ingredient + fatty acid + cholate; active ingredient + fatty acid + preservative; active ingredient + fatty acid + metal ion chelating agent;
active ingredient + surfactant + co-surfactant; active ingredient + surfactant + antioxidant; active ingredient + surfactant + cholate; active ingredient + surfactant + preservative; active ingredient + surfactant + metal ion chelating agent;
active ingredient + cosurfactant + antioxidant; active ingredient + co-surfactant + cholate; active ingredient + co-surfactant + preservative; active ingredient + co-surfactant + metal ion chelating agent;
active ingredient + antioxidant + cholate; active ingredient + antioxidant + preservative; active ingredient + antioxidant + metal ion chelating agent;
active ingredient + cholate + preservative; active ingredient + cholate + metal ion chelator;
active ingredient + preservative + metal ion chelating agent;
③ four components: "active ingredient" + "any three of fatty acid, surfactant, co-surfactant, antioxidant, cholate, preservative, metal ion chelator", for example:
active ingredient + fatty acid + surfactant + co-surfactant; active ingredients, fatty acid, surfactant and antioxidant; active ingredient + fatty acid + surfactant + cholate; active ingredient + fatty acid + surfactant + preservative; active ingredient + fatty acid + surfactant + metal ion chelating agent;
active ingredients, fatty acid, cosurfactant and antioxidant; active ingredient + fatty acid + co-surfactant + cholate; active ingredient + fatty acid + co-surfactant + preservative; active ingredient + fatty acid + co-surfactant + metal ion chelating agent;
active ingredient + fatty acid + antioxidant + cholate; active ingredients, fatty acid, antioxidant and preservative; active ingredient + fatty acid + antioxidant + metal ion chelating agent;
active ingredient + fatty acid + cholate + preservative; active ingredient + fatty acid + cholate + metal ion chelator;
active ingredient + fatty acid + preservative + metal ion chelating agent;
active ingredient + surfactant + cosurfactant + antioxidant; active ingredient + surfactant + co-surfactant + cholate; active ingredient + surfactant + co-surfactant + preservative; active ingredient + surfactant + co-surfactant + metal ion chelating agent;
active ingredient + surfactant + antioxidant + cholate; active ingredients, surfactant, antioxidant and preservative; active ingredient + surfactant + antioxidant + metal ion chelating agent;
active ingredient + surfactant + cholate + preservative; active ingredient + surfactant + cholate + metal ion chelator;
active ingredient + surfactant + preservative + metal ion chelating agent;
active ingredient + cosurfactant + antioxidant + cholate; active ingredients, cosurfactant, antioxidant and preservative; active ingredient + cosurfactant + antioxidant + metal ion chelating agent;
active ingredient + cosurfactant + cholate + preservative; active ingredient + co-surfactant + cholate + metal ion chelator;
active ingredient + co-surfactant + preservative + metal ion chelating agent;
active ingredients, antioxidant, cholate and preservative; active ingredient + antioxidant + cholate + metal ion chelator;
active ingredient + antioxidant + preservative + metal ion chelating agent;
active ingredient + cholate + preservative + metal ion chelating agent;
fourthly, five components: "active ingredient" + "any four of fatty acids, surfactants, co-surfactants, antioxidants, cholates, preservatives, metal ion chelators", for example:
active ingredients, fatty acid, surfactant, cosurfactant and antioxidant; active ingredient + fatty acid + surfactant + co-surfactant + cholate; active ingredients, fatty acid, surfactant, cosurfactant and preservative; active ingredient + fatty acid + surfactant + co-surfactant + metal ion chelating agent;
active ingredients, fatty acid, surfactant, antioxidant and cholate; active ingredients, fatty acid, surfactant, antioxidant and preservative; active ingredients, fatty acid, surfactant, antioxidant and metal ion chelating agent;
active ingredients + fatty acid + surfactant + cholate + preservative; active ingredient + fatty acid + surfactant + cholate + metal ion chelator;
active ingredient + fatty acid + surfactant + preservative + metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant and cholate; active ingredients, fatty acid, cosurfactant, antioxidant and preservative; active ingredients, fatty acid, cosurfactant, antioxidant and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, cholate and preservative; active ingredient + fatty acid + cosurfactant + cholate + metal ion chelating agent;
active ingredient + fatty acid + cosurfactant + preservative + metal ion chelating agent;
active ingredients, fatty acid, antioxidant, cholate and preservative; active ingredients + fatty acid + antioxidant + cholate + metal ion chelating agent;
active ingredients, fatty acid, antioxidant, preservative and metal ion chelating agent;
active ingredient + fatty acid + cholate + preservative + metal ion chelating agent;
active ingredient + surfactant + cosurfactant + antioxidant + cholate; active ingredients, surfactant, cosurfactant, antioxidant and preservative; active ingredient + surfactant + cosurfactant + antioxidant + metal ion chelating agent;
active ingredients, surfactant, cosurfactant, cholate and preservative; active ingredient + surfactant + co-surfactant + cholate + metal ion chelating agent;
active ingredient + surfactant + co-surfactant + preservative + metal ion chelating agent;
active ingredients, surfactant, antioxidant, cholate and preservative; active ingredient + surfactant + antioxidant + cholate + metal ion chelating agent;
active ingredients, surfactant, antioxidant, preservative and metal ion chelating agent;
active ingredient + surfactant + cholate + preservative + metal ion chelating agent;
active ingredients, cosurfactant, antioxidant, cholate and preservative; active ingredient, cosurfactant, antioxidant, cholate and metal ion chelating agent;
active ingredient + cosurfactant + cholate + preservative + metal ion chelating agent;
active ingredients, antioxidant, cholate, preservative and metal ion chelating agent;
the fifth component: "active ingredient" + "any five of fatty acids, surfactants, co-surfactants, antioxidants, cholates, preservatives, metal ion chelators", for example:
active ingredients, cosurfactant, antioxidant, cholate, preservative and metal ion chelating agent;
active ingredients, surfactant, antioxidant, cholate, preservative and metal ion chelating agent;
active ingredient + surfactant + cosurfactant + cholate + preservative + metal ion chelating agent;
active ingredient, surfactant, cosurfactant, antioxidant, cholate and metal ion chelating agent;
active ingredients, surfactant, cosurfactant, antioxidant, cholate and preservative;
active ingredients, fatty acid, antioxidant, cholate, preservative and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, cholate, preservative and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant, preservative and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant, cholate and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant, cholate and preservative;
active ingredient + fatty acid + surfactant + cholate + preservative + metal ion chelating agent;
active ingredients, fatty acid, surfactant, antioxidant, preservative and metal ion chelating agent;
active ingredients, fatty acid, surfactant, antioxidant, cholate and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant, cholate and preservative;
active ingredient + fatty acid + surfactant + co-surfactant + preservative + metal ion chelating agent;
active ingredient + fatty acid + surfactant + co-surfactant + cholate + metal ion chelating agent;
active ingredients, fatty acid, surfactant, cosurfactant, cholate and preservative;
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant and metal ion chelating agent;
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant and preservative;
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant and cholate;
sixthly, the components: "active ingredient" + "any six of fatty acids, surfactants, co-surfactants, antioxidants, cholates, preservatives, metal ion chelators", for example:
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant, cholate and preservative;
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant, cholate and metal ion chelating agent;
active ingredients, fatty acid, surfactant, cosurfactant, antioxidant, preservative and metal ion chelating agent;
active ingredients, fatty acid, surfactant, cosurfactant, cholate, preservative and metal ion chelating agent;
active ingredients, fatty acid, surfactant, antioxidant, cholate, preservative and metal ion chelating agent;
active ingredients, fatty acid, cosurfactant, antioxidant, cholate, preservative and metal ion chelating agent;
active ingredients, surfactant, cosurfactant, antioxidant, cholate, preservative and metal ion chelating agent;
seventhly, the components: active ingredients, fatty acid, surfactant, cosurfactant, antioxidant, cholate, preservative and metal ion chelating agent.
The invention also provides a preparation method of the abiraterone medicinal composition, which comprises the following steps: mixing the active ingredient and the rest components, and dissolving;
further, mixing and dissolving the active ingredients and the fatty acid, and then adding other components; or mixing the components except for the active ingredient, and mixing with the active ingredient for dissolving.
Further, the mixing and dissolving method is selected from one or more of stirring, ultrasound and heating.
The invention also provides application of the abiraterone medicinal composition in preparation of medicinal preparations.
Further, the preparation is selected from tablets, capsules, pills, powder, granules, solutions, emulsions or suspensions, preferably tablets or capsules, and the capsules are selected from soft capsules or hard capsules.
The invention also provides an abiraterone composition, which comprises any one or more abiraterone medicine compositions and an adsorbent.
The adsorbent is a solid preparation auxiliary material commonly used in the field, has strong adsorbability to oil or water, does not cause chemical property change, and is suitable for the adsorbent meeting the condition.
For example, cellulose and its derivatives, sugars, silicates, silicas, calcium phosphate, magnesium phosphate, calcium hydrogen phosphate, croscarmellose sodium, sodium acetate, sodium bicarbonate, sodium carbonate, ammonium acetate, and the like are commonly used as adsorbent materials in the art.
Further, the adsorbent is selected from one or more of microcrystalline cellulose, lactose, starch, sorbitol, dextran, silicon dioxide, magnesium aluminum silicate, kaolin, ordered mesoporous silicate, calcium phosphate, magnesium phosphate, calcium hydrogen phosphate, croscarmellose sodium, sodium acetate, sodium bicarbonate, sodium carbonate and ammonium acetate.
In a specific embodiment of the invention, the adsorbent is selected from one or more of calcium hydrogen phosphate, sodium bicarbonate, sodium carbonate and ammonium acetate;
further, the mass dosage of the adsorbent is 0.5-10 times, preferably 1.5-5 times, and more preferably 1.8-3 times of that of the abiraterone medicine composition.
In the preparation process, the liquid abiraterone medicinal composition is adsorbed on an adsorbent, so that subsequent processing production can be carried out, and more different preparations can be prepared.
When the abiraterone pharmaceutical composition is used for preparing a preparation, the obtained liquid composition can be directly filled into a soft capsule or a hard capsule, or the liquid composition can be filled into the hard capsule or the hard capsule after being solidified by a process commonly used in the field, such as spray drying, pellet coating, melt granulation and the like, by adopting solid carrier adsorption (adsorbents include but are not limited to silicon dioxide, dextran, microcrystalline cellulose, croscarmellose sodium and the like), and then the liquid composition is filled into the hard capsule or pressed into tablets. The cured pharmaceutical composition is more stable for a long time.
The medicinal composition of the invention belongs to the technical field of self-emulsification if a surfactant and/or a cosurfactant are added, and after the medicinal composition is contacted with water, emulsion particles with small oil-in-water O/W particle size (below 500 nm) can be formed by slight stirring under the action of the surfactant and the cosurfactant, and a uniform dispersion system is formed. The medicinal composition abiraterone acetate is not easy to separate out in a solvent, formed emulsion particles can be kept stable in simulated gastrointestinal fluid, the abiraterone acetate can be protected from being hydrolyzed by lipase, volatile auxiliary materials are not involved in the composition, the components can be kept stable for a long time, and the emulsion effect cannot be changed due to the change of the content of the components in the composition during administration.
The invention has the beneficial effects that:
(1) the abiraterone acetate medicinal preparation disclosed by the invention can be used for well improving the bioavailability and the drug-loading rate by adding the fatty acid, reducing the dosage, and having good medicine taking feeling and high patient compliance.
(2) The abiraterone medicinal preparation can reduce or eliminate the difference of blood concentration before meal/after meal, and has high medication safety.
(3) The abiraterone medicinal preparation disclosed by the invention is few in components, good in stability, simple in preparation process, capable of realizing large-scale industrial production and convenient to produce and transport.
Drawings
FIG. 1 pre-prandial plasma concentration-time profiles on adult SD rats for example 1, example 2, example 3 and example 4;
figure 2 is a graph of plasma concentration after a meal versus time for example 4 and example 15 on adult SD rats.
Detailed Description
The technical solutions of the present invention are described clearly and completely below, and it is obvious that the described embodiments are some, not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Abbreviations in the detailed description of the invention have the following meanings:
RH 40: polyoxyethylene 40 hydrogenated castor oil
RH 35: polyoxyethylene 35 castor oil
BHA: tert-butyl p-hydroxyanisole
BHT: dibutylhydroxytoluene
Screening a prescription:
the preparation method comprises the following steps: mixing oleic acid, surfactant and cosurfactant, adding abiraterone acetate, and stirring or ultrasonic treating.
TABLE 1 screening of cosurfactants
Figure BDA0002880929890000101
Figure BDA0002880929890000111
As can be seen from Table 1, the content of abiraterone acetate, the type of co-surfactant, etc. all affect the state of the emulsion. Generally, the smaller the content of the abiraterone acetate is, the better the emulsifying effect is, but the too small content of the abiraterone acetate can cause the increase of the clinical medication volume and reduce the compliance of patients. Under the condition of the same content of abiraterone acetate, the selection of propylene glycol as the co-emulsifier is obviously superior to PEG400, polyglycerol oleate and diethylene glycol monoethyl ether.
TABLE 2
Figure BDA0002880929890000112
As can be seen from table 2, the emulsifying effect of surfactant tween 80 is close to that of caprylic capric acid macrogol glyceride.
TABLE 3
Figure BDA0002880929890000113
Figure BDA0002880929890000121
The preparation method of the formula 15-22 comprises the following steps: mixing oleic acid or acetic acid with other adjuvants, adding abiraterone acetate, and stirring or ultrasonic treating.
As can be seen from Table 3, the above formulations all formed clear and transparent nanoemulsion solutions in water.
TABLE 4
Figure BDA0002880929890000122
The preparation method of the formula 23-29 comprises the following steps: mixing oleic acid, RH35 and propylene glycol uniformly, adding abiraterone acetate, stirring or ultrasonic treating to dissolve completely to form a uniform clear solution; the solution is then mixed with an adsorbent material to be completely adsorbed by the adsorbent.
The results in table 4 show that the pharmaceutical composition of the present invention can form clear and transparent nanoemulsion solution in water after being treated by different adsorbents.
Example 1
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
name ratio (mass ratio)
Abiraterone acetate 28.6%
Oleic acid 71.4%
The preparation method comprises the following steps: adding abiraterone acetate into oleic acid, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate, and forming a uniform and clear solution.
The human stomach and intestine also secrete a large amount of bile salts, and the phospholipids in the human body can self-emulsify oil-soluble substances, so the embodiment is the simplest combination of the embodiment of the invention.
Example 2
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000131
the preparation method comprises the following steps: mixing oleic acid, polyoxyethylene 40 hydrogenated castor oil and propylene glycol uniformly, adding abiraterone acetate, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate to form a uniform and clear solution.
Example 3
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000132
the preparation method comprises the following steps: mixing oleic acid, polyoxyethylene 35 castor oil and propylene glycol uniformly, adding abiraterone acetate, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate to form a uniform and clear solution.
Example 4
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000133
the preparation method comprises the following steps: mixing oleic acid, polyoxyethylene 40 hydrogenated castor oil and propylene glycol uniformly, adding abiraterone acetate, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate to form a uniform and clear solution.
Example 5
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000141
the preparation method comprises the following steps: mixing abiraterone acetate and oleic acid, sequentially adding polyoxyethylene 35 castor oil and propylene glycol, mixing, stirring or ultrasonic treating to dissolve completely to obtain a uniform and clear solution.
Example 6 this example provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000142
the preparation method comprises the following steps: mixing oleic acid, polyoxyethylene 40 hydrogenated castor oil and diethylene glycol monoethyl ether uniformly, adding abiraterone acetate, stirring or ultrasonic treating to dissolve completely to form a uniform and clear solution.
Example 7
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000143
the preparation method comprises the following steps: mixing oleic acid, caprylic/capric polyethylene glycol glyceride and propylene glycol uniformly, adding abiraterone acetate, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate to form a uniform and clear solution.
Example 8
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000151
the preparation method comprises the following steps: mixing oleic acid, polyethylene glycol 15 hydroxy stearate and diethylene glycol monoethyl ether uniformly, adding abiraterone acetate, stirring or performing ultrasonic treatment to completely dissolve the abiraterone acetate to form a uniform and clear solution.
Example 9
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000152
the preparation method comprises the following steps: mixing oleic acid, Tween 80 and diethylene glycol monoethyl ether, adding abiraterone acetate, stirring or ultrasonic treating to dissolve completely to obtain a uniform and clear solution, and filling into soft capsule or canning into hard capsule under nitrogen protection.
Example 10
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000153
the preparation method comprises the following steps: mixing oleic acid, Tween 80 and propylene glycol, adding abiraterone acetate, stirring or ultrasonic treating to dissolve completely to obtain a uniform and clear solution, and filling into soft capsule or canning into hard capsule under nitrogen protection.
Example 11
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000161
the preparation method comprises the following steps: mixing oleic acid, polyethylene glycol 15 hydroxy stearate, and propylene glycol, adding abiraterone acetate, stirring or ultrasonic treating to dissolve completely to obtain uniform clear solution, and filling into soft capsule or canning into hard capsule under nitrogen protection.
Example 12
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000162
the preparation method comprises the following steps: dissolving abiraterone acetate in oleic acid, adding glycerol monolinoleate, hydrogenated castor oil and propylene glycol, stirring at 400rpm, mixing completely to obtain a uniform and clear solution, and filling into soft capsule or canning into hard capsule under nitrogen protection.
Example 13
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000163
the preparation method comprises the following steps: dissolving abiraterone acetate in acetic acid, adding propylene glycol monocaprylate, hydrogenated castor oil and propylene glycol, stirring at 400rpm, mixing completely to obtain a uniform and clear solution, and filling into soft capsules or canning into hard capsules under the protection of nitrogen.
Example 14
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000171
the preparation method comprises the following steps: dissolving abiraterone acetate in oleic acid, adding propylene glycol monocaprylate, hydrogenated castor oil and propylene glycol, stirring at 400rpm, mixing completely to obtain a uniform and clear solution, and filling into soft capsules or canning into hard capsules under the protection of nitrogen.
Example 15
The embodiment provides a pharmaceutical composition containing abiraterone acetate, wherein the composition comprises the following components in parts by mass:
Figure BDA0002880929890000172
the preparation method comprises the following steps:
dissolving abiraterone acetate in oleic acid, dissolving BHA and BHT in propylene glycol, mixing the two mixed solutions, adding propylene glycol monolaurate and hydrogenated castor oil, stirring at 400rpm, mixing completely to obtain a uniform and clear solution, and filling into soft capsule or packaging into hard capsule under nitrogen protection.
The related performance and quality of the pharmaceutical composition of the invention are examined, and in the following test examples, all tests related to hard capsules are obtained by filling the pharmaceutical composition of the invention into No. 1 hard capsules, the filling amount is between 0.5g and 1.0g, and the actual filling amount of the hard capsules used in the test examples is 0.7 g.
The related performance and quality of the pharmaceutical composition of the invention are examined, and in the following test examples, all tests related to hard capsules are obtained by filling the pharmaceutical composition of the invention into No. 1 hard capsules, the filling amount is between 0.5g and 1.0g, and the actual filling amount of the hard capsules used in the test examples is 0.7 g.
Test example 1
The pharmaceutical compositions of the examples were tested for their emulsified state in water and their average particle size after emulsification: taking 0.5ml of the pharmaceutical composition of the invention, taking 8ml of water in addition, heating to 37 ℃ in a water bath, slowly dripping 0.5ml of the pharmaceutical composition into 8ml of water while stirring, observing the phenomenon after emulsification, and detecting the particle size of emulsion particles. The order of merits of the emulsified state is: the transparency is more than semitransparent, more than grey-white milky, more than blue milky and more than milky white milky, and the detection results are shown in Table 6.
TABLE 5
Sample (I) Emulsified state Particle size of milk particles
Example 2 Transparent to translucent emulsions 39nm
Example 3 Transparent to translucent emulsions 28nm
Example 4 Translucent to off-white emulsion 124nm
Example 5 Translucent to off-white emulsion 87nm
As can be seen from the data in Table 5, examples 2 to 3 had the best emulsification properties in water, and were transparent to translucent emulsions, followed by examples 4 to 5.
Test example 2
The pharmaceutical compositions of examples 2 to 4 were subjected to dissolution measurement using a hydrochloric acid medium having a pH of 1.0 and a phosphate medium having a pH of 6.8, respectively.
Dissolution conditions: medium 1 is a hydrochloric acid solution medium at ph1.0 and medium 2 is a phosphate buffer solution medium at ph 6.8. The dissolving-out method is a slurry method, the rotating speed is 75r/min, the medium temperature is 37 ℃, the medium volume is 900ml, and a 0.45um filter membrane is adopted for filtration after sampling.
Dissolution test investigation samples:
the original preparation: trade name Zytiga, size 250mg, tablet;
self-made preparation: the pharmaceutical compositions of examples 1-7 were filled into hard capsules.
The dissolution measurement results are shown in tables 6 and 7
TABLE 6 dissolution in hydrochloric acid medium at pH1.0
Figure BDA0002880929890000181
TABLE 7 phosphate buffer medium pH6.8
Figure BDA0002880929890000191
As can be seen from the results of tables 6 and 7, the capsules of the pharmaceutical composition of the present invention showed higher dissolution rates in media of pH1.0 and pH6.8, while the original formulation Zytiga showed little dissolution rate and was not substantially dissolved. The medicinal composition has higher dissolution rate, which indicates that the medicinal composition can be quickly dissolved in gastrointestinal tracts, and the dissolution rate of the abiraterone acetate is higher than that of the original research, so that the medicinal composition is favorable for improving the bioavailability of the medicament.
Test example 3
Evaluation of simulated gastric digestion of pharmaceutical compositions: the auxiliary materials of the medicinal composition are mostly oily ester auxiliary materials, and the medicinal composition can be digested in vivo, and the digestion of the oily ester auxiliary materials can cause the particle size of emulsion particles to be enlarged or cause precipitation of abiraterone acetate to influence the absorption of the medicament. Abiraterone acetate is easily hydrolyzed into abiraterone in the gastrointestinal tract, the abiraterone is poor in dissolution and permeation, and if the abiraterone acetate is hydrolyzed more, the absorption of the medicine in the body is influenced to a certain extent.
The present invention was digested with FaSSIF (from Biorelevant) simulating gastric juice in the stomach and the original formulation was used to evaluate the stability in the stomach. The adopted method is to prepare solution according to the preparation method of FaSSIF provided by Biorelevant company, 50ml of the prepared FaSSIF is taken and heated under the condition of 37 ℃ water bath, 1ml of the composition is taken and added into the FaSSIF solution while stirring, the stirring is continued for 4 hours, the state of the emulsion is observed, and the contents of abiraterone acetate and abiraterone are sampled and detected at 0 hour, 2 hours and 4 hours.
TABLE 8 results of the data for the evaluation of the gastric digestion of the pharmaceutical composition of the present invention
Figure BDA0002880929890000192
As can be seen from the data in Table 8, the amount of abiraterone acetate hydrolyzed into abiraterone in the pharmaceutical composition is obviously smaller than that of the original preparation, which indicates that the pharmaceutical composition has a certain protective effect on the stability of the abiraterone acetate in the stomach and can further increase the bioavailability of the prescription.
Test example 4 influence factor test
The formulation of example 5 was left at 60 ℃ for 10 days, and the results are shown in Table 9.
TABLE 9 example 5 stability test at 60 ℃ at elevated temperature
Figure BDA0002880929890000201
The experimental result shows that the prescription of the invention in example 5 has good stability, and compared with the prescription using oleic acid reported in patent CN105055314A that the total impurity reaches 1.1% at 15-20 ℃ on the preparation day, the prescription of the invention in example 5 has significantly better stability, and can control the impurities at a lower level, and the most significant impurities in the generated impurities are abiraterone, which is an active substance actually taking effect after the abiraterone acetate enters the body.
Test example 5 Experimental data for rat Synthesis
The experimental scheme is as follows:
adult SD male rats, randomly grouped, 3 per group;
experiment design: fasting single gastric lavage is carried out, fasting is carried out for more than 10 hours before the experiment, and feeding is carried out 4 hours after the administration; administration dose: 90 mg/kg; blood sampling time points: 15min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h and 12 h.
Control group: the original formulation Zytiga, 250mg in size, was prepared by grinding tablets into powder, dispersing with water and then administering.
The pharmacokinetic parameters of the original formulation Zytiga and the formulations of examples 1-4 tested in rats are shown in table 10 and fig. 1:
watch 10
Figure BDA0002880929890000202
Figure BDA0002880929890000211
Where Tmax is the time to peak, Cmax is the maximum plasma concentration, and AUC (last) is the AUC, i.e. the area of the curve at drug time, of the duration from the beginning of the administration to the last blood sampling point, the graph of the time curve of the original formulation Zytiga in rats under fasting condition with drugs of examples 1, 2, 3, and 4 is shown in fig. 1.
As can be seen from Table 3, the exposure of examples 1, 2, 3 and 4 in rats was higher than that of the original preparation, and the bioavailability was improved to 7.1 times.
Test example 6 examination of bioavailability of examples 4 and 15 after a meal in SD rats
The experimental scheme is as follows:
adult SD male rats, randomly grouped, 4 per group;
experiment design:
fasting group: single gastric lavage administration, fasting for more than 10 hours before experiment, and feeding for 4 hours after administration;
postprandial group: administration within half an hour after meal
Administration dose: 90 mg/kg;
blood sampling time points: 15min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h and 10 h.
The pharmacokinetic parameters of the drug solutions of example 4 and example 15 before and after meals in SD rats are shown in Table 11 and FIG. 2:
table 11 partial pharmacokinetic parameters of example 4 and example 15 on male SD rats
Figure BDA0002880929890000212
The pharmacokinetic data for example 4 show that the bioavailability of the formula after meal was 51.69%, 37.27% respectively, with a postprandial exposure of 0.72 times the preprandial exposure. The pharmacokinetic data for example 15 show that the bioavailability of the formula after meal is 41.26%, 31.99% respectively, with a 0.78-fold post-meal exposure compared to the pre-meal exposure. It was reported that Zytiga given with a low fat diet (7% fat, 300 calories) increased abiraterone Cmax and AUC 0- ∞about7-fold and 5-fold, respectively; abiraterone Cmax and AUC 0- ∞ increase about 17-fold and 10-fold, respectively, when given with a high fat diet (57% fat, 825 calories).
Test example 7 examination of pharmacokinetics in beagle dogs of example 4 and example 14
The experimental scheme is as follows:
male beagle dogs, randomly grouped, 2 per group;
experiment design: animals were fasted the day before dosing (fasting time 10-18 hours) and given regular diet 4h after dosing.
Administration dose: from preparation, 50 mg/preparation, from original preparation, 500 mg/preparation (2 tablets)
Blood sampling time points: 15min, 30min, 1h, 2h, 4h, 6h, 8h and 24 h.
The pharmacokinetics of example 4 and example 14 before the meal of male beagle dogs are shown in table 12.
Table 12 comparison of pharmacokinetic parameters of example 4, example 14 and the original study before meal consumption in male beagle dogs
Original research Example 4 Example 14
Cmax(ug/L) 126.44 530.24 470.31
AUC0-t(ug/L*h) 278.36 986.38 610.87
Tmax(h) 0.63 1.00 0.50
The Cmax, AUC (0-t) and Tmax for 50mg of the test formulation (example 4) were 530.24ug/L, 986.38ug/L × h and 1.00h, respectively, and 4.19, 3.54 and 1.59 times greater than for 500mg of the original formulation, respectively, administered fasted.
The Cmax, AUC (0-t) and Tmax for 50mg of the test formulation (example 14) were 470.31ug/L, 610.87ug/L × h and 0.50h, respectively, 3.72, 2.19 and 0.79 times those for 500mg of the original formulation, administered fasted.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (22)

1. An oral abiraterone medicinal composition is characterized by comprising an active ingredient and an oil solvent, wherein the active ingredient is abiraterone acetate and/or abiraterone, and the oil solvent is fatty acid.
2. An abiraterone pharmaceutical composition of claim 1, which comprises the following components in parts by weight: 1-80% of active ingredients and the balance of fatty acid; further, the mass fraction of the active ingredient is 1% to 50%, preferably 5% to 40%, more preferably 10% to 30%.
3. An abiraterone pharmaceutical composition according to claim 2, wherein the mass fraction of the active ingredient is 4% -20%, preferably 4-15.5%.
4. An abiraterone pharmaceutical composition according to claim 1 or 2, wherein the fatty acid is selected from one or more of linolenic acid, oleic acid, linoleic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, eicosapentaenoic acid, docosahexaenoic acid, acetic acid, preferably linolenic acid and/or oleic acid, more preferably oleic acid.
5. An oral abiraterone pharmaceutical composition is characterized by comprising an active ingredient and a surfactant, wherein the active ingredient is abiraterone acetate and/or abiraterone;
further, the mass fraction of the surfactant is 0% to 70%, preferably 10% to 55%, more preferably 20% to 30%.
6. An abiraterone composition of claim 5, wherein the mass fraction of the surfactant is 20-50%.
7. An abiraterone pharmaceutical composition of claim 5, wherein the surfactant is selected from nonionic surfactants having HLB value greater than 8, and further selected from one or more of polysorbate surfactants, polyoxyethylene fatty acid ester surfactants, polyoxyethylene fatty alcohol ether surfactants, polyoxyethylene-polyoxypropylene copolymer surfactants, and soluplus;
further, the surfactant is selected from one or more of caprylic/capric acid polydiethylene glycol glyceride, tween 80, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene 35 castor oil and polyethylene glycol 15 hydroxystearate, preferably one or more of tween 80, polyoxyethylene 40 hydrogenated castor oil and polyoxyethylene 35 castor oil, and more preferably polyoxyethylene 40 hydrogenated castor oil and/or polyoxyethylene 35 castor oil.
8. An oral abiraterone pharmaceutical composition is characterized by comprising an active ingredient and a cosurfactant, wherein the active ingredient is abiraterone acetate and/or abiraterone;
further, the mass fraction of the co-surfactant is 0% to 70%, preferably 10% to 55%, more preferably 20% to 30%.
9. An abiraterone pharmaceutical composition according to claim 8, wherein the mass fraction of the co-surfactant is 0% to 50%, preferably 5% to 40%.
10. An abiraterone pharmaceutical composition according to claim 8, wherein the co-surfactant is selected from one or more of propylene glycol, ethanol, PEG400, glycerol, diethylene glycol monoethyl ether, caprylic capric acid polyethylene glycol glyceride, polyglycerol oleate, propylene glycol monocaprylate, oleic acid polyethylene glycol glyceride, further selected from one or more of propylene glycol, ethanol, PEG400, glycerol, diethylene glycol monoethyl ether, preferably propylene glycol and/or diethylene glycol monoethyl ether, more preferably propylene glycol.
11. An oral abiraterone medicinal composition is characterized by comprising the following components in parts by weight: 5 to 40 percent of abiraterone acetate, 10 to 75 percent of oleic acid, 10 to 55 percent of surfactant and 10 to 40 percent of cosurfactant;
further, the composition comprises the following components in parts by weight: 10 to 30 percent of abiraterone acetate, 30 to 50 percent of oleic acid, 20 to 40 percent of surfactant and 15 to 30 percent of cosurfactant;
further, the composition comprises the following components in parts by weight: 15.2% abiraterone acetate, 38.2% oleic acid, 23.3% polyoxyethylene 35 castor oil and 23.3% propylene glycol, or 12.3% abiraterone acetate, 30.7% oleic acid, 28.5% polyoxyethylene 35 castor oil and 28.5% propylene glycol, or 10.3% abiraterone acetate, 22.5% oleic acid, 33.6% polyoxyethylene 35 castor oil and 33.6% propylene glycol, or 7.4% abiraterone acetate, 18.5% oleic acid, 37.3% polyoxyethylene 35 castor oil and 36.8% propylene glycol, or 4.0% abiraterone acetate, 10.1% oleic acid, 47.5% polyoxyethylene 35 castor oil and 38.4% propylene glycol.
12. An oral abiraterone pharmaceutical composition is characterized by comprising an active component and an antioxidant; further, the content of the antioxidant is 0.005-0.5%, preferably 0.01-0.2%.
13. An abiraterone pharmaceutical composition of claim 12, wherein the antioxidant is selected from t-butyl p-hydroxyanisole and/or dibutyl hydroxytoluene.
14. An oral abiraterone pharmaceutical composition is characterized by comprising an active component and cholate; furthermore, the content of the cholate is 20-70%.
15. An abiraterone pharmaceutical composition of claim 14, wherein the cholate is sodium glycocholate and/or sodium taurocholate.
16. An oral abiraterone composition, comprising an abiraterone pharmaceutical composition of any of claims 1-15 and an adsorbent; further, the adsorbent is selected from one or more of cellulose and derivatives thereof, saccharides, silicates, silicon dioxide, calcium phosphate, magnesium phosphate, calcium hydrogen phosphate, croscarmellose sodium, sodium bicarbonate, sodium acetate, sodium carbonate and ammonium acetate;
further, the adsorbent is selected from one or more of microcrystalline cellulose, lactose, starch, sorbitol, dextran, silicon dioxide, magnesium aluminum silicate, kaolin, ordered mesoporous silicate, calcium phosphate, magnesium phosphate, calcium hydrogen phosphate, croscarmellose sodium, sodium bicarbonate, sodium acetate, sodium carbonate and ammonium acetate.
17. An abiraterone composition as claimed in claim 16, wherein the adsorbent is selected from one or more of calcium hydrogen phosphate, sodium bicarbonate, sodium carbonate, ammonium acetate;
further, the mass amount of the adsorbent is 0.5-10 times, preferably 1.5-5 times, and more preferably 1.8-3 times of that of the abiraterone medicine composition of any one of claims 1-12.
18. A process for the preparation of an abiraterone pharmaceutical composition of any of claims 1 to 15, comprising: mixing the active ingredient and the rest components, and dissolving;
further, mixing and dissolving the active ingredients and the fatty acid, and then adding other components; or mixing the components except for the active ingredient, and mixing with the active ingredient for dissolving.
19. The preparation method of claim 18, wherein the mixing and dissolving method is selected from one or more of stirring, ultrasound and heating.
20. A process for the preparation of an abiraterone composition of claim 16 or 17, which comprises the following: adsorbing the abiraterone pharmaceutical composition of any of claims 1-15 onto an adsorbent.
21. Use of an abiraterone composition of any of claims 1 to 17 or an abiraterone composition in the preparation of an oral pharmaceutical formulation.
22. Use according to claim 21, wherein the formulation is selected from tablets, capsules, pills, powders, granules, solutions, emulsions or suspensions, preferably tablets or capsules selected from soft or hard capsules.
CN202011642502.6A 2020-06-01 2020-12-31 Oral abiraterone pharmaceutical composition, preparation method and application thereof Active CN113750032B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020104848725 2020-06-01
CN202010484872 2020-06-01

Publications (2)

Publication Number Publication Date
CN113750032A true CN113750032A (en) 2021-12-07
CN113750032B CN113750032B (en) 2024-07-16

Family

ID=78786244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011642502.6A Active CN113750032B (en) 2020-06-01 2020-12-31 Oral abiraterone pharmaceutical composition, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113750032B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306236A (en) * 2021-12-15 2022-04-12 湖南慧泽生物医药科技有限公司 Self-microemulsion system for loading abiraterone acetate, composition and application
WO2023109758A1 (en) * 2021-12-15 2023-06-22 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013331A2 (en) * 2010-07-26 2012-02-02 Gp-Pharm, S.A. Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
CN102961358A (en) * 2012-11-29 2013-03-13 重庆医药工业研究院有限责任公司 Abiraterone acetate liquid capsule
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
US20150133416A1 (en) * 2012-05-04 2015-05-14 Jagotec Ag Pharmaceutical Composition Comprising Abiraterone Acetate
CN105055314A (en) * 2015-09-28 2015-11-18 杭州安德科技有限公司 Abiraterone oral spray and use and preparation methods thereof
CN105535979A (en) * 2015-11-22 2016-05-04 李素华 Self-emulsifying drug delivery system for improving bioavailability of insoluble medicine, and application thereof
CN106692051A (en) * 2015-08-18 2017-05-24 南京诺瑞特医药科技有限公司 Preparation of 17-(3-pyridine)-androst-4, 6-diene-3-one
WO2019042247A1 (en) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 Pharmaceutical composition of cyp17 inhibitor and preparation method therefor
CN110538150A (en) * 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 Medicinal composition containing abiraterone acetate and preparation method and application thereof
CN111012745A (en) * 2020-01-06 2020-04-17 深圳海王医药科技研究院有限公司 Abiraterone oral emulsion and preparation method thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013331A2 (en) * 2010-07-26 2012-02-02 Gp-Pharm, S.A. Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
US20150133416A1 (en) * 2012-05-04 2015-05-14 Jagotec Ag Pharmaceutical Composition Comprising Abiraterone Acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102961358A (en) * 2012-11-29 2013-03-13 重庆医药工业研究院有限责任公司 Abiraterone acetate liquid capsule
CN106692051A (en) * 2015-08-18 2017-05-24 南京诺瑞特医药科技有限公司 Preparation of 17-(3-pyridine)-androst-4, 6-diene-3-one
CN105055314A (en) * 2015-09-28 2015-11-18 杭州安德科技有限公司 Abiraterone oral spray and use and preparation methods thereof
CN105535979A (en) * 2015-11-22 2016-05-04 李素华 Self-emulsifying drug delivery system for improving bioavailability of insoluble medicine, and application thereof
WO2019042247A1 (en) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 Pharmaceutical composition of cyp17 inhibitor and preparation method therefor
CN110538150A (en) * 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 Medicinal composition containing abiraterone acetate and preparation method and application thereof
CN111012745A (en) * 2020-01-06 2020-04-17 深圳海王医药科技研究院有限公司 Abiraterone oral emulsion and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306236A (en) * 2021-12-15 2022-04-12 湖南慧泽生物医药科技有限公司 Self-microemulsion system for loading abiraterone acetate, composition and application
WO2023109758A1 (en) * 2021-12-15 2023-06-22 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
US11806313B2 (en) 2021-12-15 2023-11-07 Hunan Huize Biopharma S&T Co., Ltd. Abiraterone acetate containing composition and application thereof

Also Published As

Publication number Publication date
CN113750032B (en) 2024-07-16

Similar Documents

Publication Publication Date Title
EP4035657A1 (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
JP2018024685A (en) Natural combination hormone replacement formulations and therapies
EP2205219B1 (en) Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
WO2023000873A1 (en) Abiraterone acetate soft capsule and preparation method therefor and application thereof
RU2015144285A (en) COMPOSITION BASED ON ACETATE ABIATERON
JP2016104782A (en) Rifaximin ready-to-use suspension
WO2006021160A1 (en) Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application
CN113750032B (en) Oral abiraterone pharmaceutical composition, preparation method and application thereof
EP1249230B1 (en) Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10
MX2011002847A (en) Composite organic compound powder for medical use, method for producing same and suspension of same.
JP2008536879A (en) Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof
TW201127386A (en) Bazedoxifene formulations with antioxidants
US20020028794A1 (en) Megestrol acetate suspension
JP7301883B2 (en) HC-1119 Formulations and Methods of Making and Using Themselves
BRPI0612665A2 (en) nanoparticulate megestrol formulations
US20160089437A1 (en) Flocculated megestrol acetate suspension
PT1494649E (en) Nanoparticulate megestrol formulations
CN109692155A (en) A kind of preparation method and application of polyether antibiotics unsaturated fatty acid compound oily solution
CN114762693A (en) Abiraterone pharmaceutical composition with high drug loading rate as well as preparation method and application thereof
CN116173018A (en) Darotamine pharmaceutical composition and preparation method and application thereof
CN117883379A (en) Oral alkaline solvent composition and preparation method and application thereof
CN112957481A (en) Insoluble drug inclusion compound, inclusion method and chlortetracycline hydrochloride soluble powder
CN112043679A (en) Soft capsule preparation containing quinazoline compound and preparation method thereof
Desu et al. Liquid dosage forms
TWI828471B (en) Self-microemulsifying compositions and applications of abiraterone acetate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant